Marisa A. Fuse

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Marisa A. Fuse, Christine T. Dinh, Jérémie Vitte et al. · Neuro-Oncology · 2019 · 39 citations · Full text

Medicine, Cancer Biology, Oncology +17

A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.

Alejandra M. Petrilli, Marisa A. Fuse, Mathew S Donnan et al. · PubMed · 2014 · 36 citations · Full text

Medicine, Chemical Biology, Pharmacology +13

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells

Marisa A. Fuse, Stephani Klingeman Plati, Sarah S. Burns et al. · Molecular Cancer Therapeutics · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents

Hongfen Yang, Shivani Kundra, Michaelle Chojnacki et al. · Journal of Medicinal Chemistry · 2021 · 34 citations · Full text

Life Sciences, Medicinal Chemistry, Microbiology +17

Peroxynitrite nitration of Tyr 56 in Hsp90 induces PC12 cell death through P2X7R-dependent PTEN activation

Megan Jandy, Asra Noor, Pascal A. Nelson et al. · Redox Biology · 2022 · 30 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17